

FAXED COPY RECEIVED

JUN 24 2002

TECHNOLOGY CENTER 3700 Atty Dkt. No.: PALX-002CON
USSN: 09/828,539

B¹
Came
visibility composition may further include additional radiopaque particles or contrast particles mixed in with the composition, which have a particle size between about 120 μ and 350 μ , preferably between about 120 μ and 250 μ .

IN THE CLAIMSClaims 33-43 should read as follows in view of this Amendment and the Second PreliminaryAmendment filed December 17, 2001:

33. An injectable composition comprising:

a biocompatible matrix;

radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size between about 120 μ and 2200 μ ; and

liquid contrast agent.

34. The injectable composition of claim 33, wherein said biocompatible matrix and said radiopaque particles form a slurry.

35. The injectable composition of claim 33, wherein the mixture of said biocompatible matrix and said radiopaque particles forms a hard tissue implant material.

36. The injectable composition of claim 33, wherein said radiopaque particles have a particle size between about 350 μ and 2200 μ .

37. The injectable composition of claim 36, further comprising:

radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .38. The injectable composition of claim 36, wherein said radiopaque particles have a particle size between about 450 μ and 1600 μ .39. The injectable composition of claim 38, wherein said radiopaque particles having a particle size between about 570 μ and 1150 μ .

40. An enhanced visibility composition comprising:

a flowable matrix; and

radiopaque particles in said flowable matrix, said radiopaque particles having a size between about 350 μ and about 2200 μ so as to be individually visible during implantation.41. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 570 μ and 2200 μ .B²
546
D27
42. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 450 μ and 1600 μ .

JUN 24 2002

TECHNOLOGY CENTER 3700A Dkt. No.: PALX-002CON
USSN: 09/828,539

new
43. The enhanced visibility/composition of claim 40, wherein said radiopaque particles have a size between about 570 μ and 1150 μ .

Please enter the following new claims, corresponding to original claims 33-41, except to the extent explained in the Remarks below

Sub D 37 44. (New) The injectable composition of claim 40, further comprising:

radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .

45. (New) The injectable composition of claim 40, further comprising:

radiopaque particles for contrast having a particle size up to about 350 μ .

46. (New) The injectable composition of claim 36, further comprising:

radiopaque particles for contrast having a particle size up to about 350 μ .

47. (New) An injectable composition comprising:

B4 a hard tissue implant biocompatible matrix; and

radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size between about 120 μ and 2200 μ .

48. (New) The injectable composition of claim 47, wherein said biocompatible matrix and said radiopaque particles form a slurry.

49. (New) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 350 μ and 2200 μ .

50. (New) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 450 μ and 1600 μ .

51. (New) The injectable composition of claim 50, wherein said radiopaque particles have a particle size between about 570 μ and 1150 μ .

52. (New) The injectable composition of claim 49, further comprising:

radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .

53. (New) The injectable composition of claim 49, further comprising:

radiopaque particles for contrast having a particle size up to about 350 μ .

REMARKS

Formal Matters

Claims 33-53 are pending after entry of the amendments set forth herein.

Claims 33-41 were examined in the Office Action dated December 19, 2001 prior to entry of the Second Preliminary Amendment filed by Applicant on December 4, 2001. As such, claims 33-41 as